• Adrian Adams, President and Chief Executive Officer
• Mark H.N. Corrigan, M.D., Executive Vice President, Research and Development
• Mark Iwicki, Executive Vice President and Chief Commercial Officer
  
• Andrew I. Koven, Executive Vice President, General Counsel and Corporate Secretary
• Robert F. Scumaci, Executive Vice President and Chief Financial Officer

Adrian Adams
President and Chief Executive Officer

Mr. Adams joined Sepracor in March 2007 as President and Chief Operating Officer and, in May 2007, became President and Chief Executive Officer of the company. Most recently, Mr. Adams was with Kos Pharmaceuticals, Inc., where he served as President and Chief Operating Officer from April 2001, prior to becoming President and Chief Executive Officer in January 2002. In December 2006, Mr. Adams was instrumental in the sale of Kos to Abbott Laboratories. Having spent the majority of his career in the pharmaceutical industry, Mr. Adams has extensive senior and general management experience with a broad background encompassing research and development, sales, marketing, international and national product management and business development. Mr. Adams served as President and Chief Executive Officer of Novartis-UK from 1999 until his tenure began at Kos. For the previous seven years, Mr. Adams was with SmithKline Beecham Pharmaceuticals, last serving as President and CEO of the company's Canadian subsidiaries. Previous assignments at SmithKline Beecham included Vice President and Director of Worldwide Marketing in the U.S., and Director and Vice President of Sales and Marketing in the United Kingdom.

Mr. Adams began his career at ICI Pharmaceuticals, where he rose from research laboratory assistant to Director of Sales and Marketing. During his career, he has worked in most countries of the world and has experience in most primary care, specialist and biological therapeutic areas. In addition, he has been instrumental in a number of major global and national product launches including Paxil^®, Famvir^®, Coreg^®, Diovan^®, Tenormin^® and Zestril^®. He is a graduate of Manchester University in the United Kingdom with a Bachelor of Science degree.

Mr. Adams serves as a board member of PhRMA (Pharmaceutical Research and Manufacturer of America) and Amylin Pharmaceuticals.

Mark H.N. Corrigan, M.D.
Executive Vice President, Research and Development

Dr. Corrigan joined Sepracor in 2003 as Executive Vice President of Research and Development. Prior to joining Sepracor, Dr. Corrigan joined the Upjohn Company in 1993, which became Pharmacia Corp. in 1996.  At Pharmacia, Dr. Corrigan served as Group Vice President of Global Clinical Research and Experimental Medicine and in 1998, was promoted to Group Vice President, Global Clinical Research, with responsibility for clinical research, biostatistical/data management and global procurement for compounds in Phases I-IIIB.

Prior to joining the pharmaceutical industry with the Upjohn Company, Dr. Corrigan spent several years in academic research at the University of North Carolina Medical School, focusing in psychoneuroendocrinology. During his tenure, Dr. Corrigan was a principal investigator for several novel antipsychotics and continues to maintain an appointment as Adjunct Clinical Professor of Psychiatry.

Dr. Corrigan has over twenty years of experience in treating psychiatric and central nervous system disorders and is board certified in psychiatry and neurology.

Dr. Corrigan earned his undergraduate and medical degrees from the University of Virginia and subsequently received specialty training in psychiatry at Cornell and Maine Medical Center.

Dr. Corrigan serves as a board member of Neuromed Technologies Inc. and has been elected as a Distinguished Fellow of the American Psychiatric Association (APA).

Mark Iwicki
Executive Vice President and Chief Commercial Officer

Mark Iwicki joined Sepracor in October 2007 and is Executive Vice President and Chief Commercial Officer. Mr. Iwicki is responsible for leading all aspects of Sepracor's Commercial functions, including the Sales, Marketing, Managed Care, New Products Planning, and Commercial Analytics groups.

Prior to joining Sepracor, Mr. Iwicki held senior positions at Novartis Pharmaceuticals from 1998 through 2007, most recently as Vice President and Cardiovascular Business Franchise Head. Prior to that, Mr. Iwicki was head of the Arthritis, Bone, Gastrointestinal, HRT, Infectious Disease and Urology Business Franchise Head. Before joining Novartis, Mr. Iwicki held various sales and marketing positions at Merck and Astra Merck. Mr. Iwicki earned his B.S. from Ball State University and an MBA from Loyola College.

Andrew I. Koven
Executive Vice President, General Counsel and Corporate Secretary

Prior to joining Sepracor in March 2007, Mr. Koven was Executive Vice President, General Counsel and Corporate Secretary at Kos Pharmaceuticals, Inc., which was acquired by Abbott Laboratories in December 2006. At Kos, he oversaw the legal, compliance and quality assurance functions.

From 2000 until 2003, Mr. Koven served as Senior Vice President, General Counsel and Corporate Secretary at Lavipharm Laboratories Inc., a drug delivery and specialty pharmaceutical company. Mr. Koven served in increasingly responsible roles at Warner-Lambert Company between 1993 and 2000, most recently in the position of Assistant General Counsel, Pharmaceuticals, North America.

Prior to joining Warner-Lambert, Mr. Koven was a corporate/securities associate at Cahill Gordon & Reindel in New York City. Mr. Koven earned his B.A. in 1978 from Dalhousie University in Halifax, Nova Scotia, Canada, his LL.B. in 1981 from Dalhousie Law School and his LL.M. in 1986 from Columbia University School of Law.

Robert F. Scumaci
Executive Vice President and Chief Financial Officer

Mr. Scumaci was recently appointed as Executive Vice President and Chief Financial Officer of Sepracor.  Mr. Scumaci served as Executive Vice President, Corporate Finance, Administration and Technical Operations since May 2007 and as Executive Vice President of Finance and Administration at Sepracor since February 2001.  Mr. Scumaci served as Senior Vice President of Finance and Administration at Sepracor from March 1996 to February 2001 and as Vice President and Controller from March 1995 until March 1996.

Prior to joining Sepracor, Mr. Scumaci was Vice President of Finance and Administration, North American Operations with Ares-Serono Group, a multinational pharmaceutical company from 1987 to 1994. Previously, he was associated with Revlon and Coopers & Lybrand in various finance and accounting capacities.